Business Daily from THE HINDU group of publications
Sunday, Jun 28, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
Business Daily from THE HINDU group of publications Sunday, Jun 28, 2009 ePaper | Mobile/PDA Version | Audio | Blogs |
|
|
|
|
|
Home Page
-
Pharmaceuticals Investment World - Stocks Markets - Recommendation 
Investors with medium-term perspective can consider buying Strides Arcolab stock. The structural down trend that commenced in February 2007 at Rs 396, appears to have halted around Rs 60. The stock is in a nascent intermediate term uptrend since then that has yielded almost two-fold gains. The stock has not succumbed to the correction witnessed in the market over the last two weeks and the recent uptrend has been backed by good volumes during the advancing weeks. It is currently holding well above its 50 and 200 day moving averages and both daily and weekly momentum indicators are showing strength. In medium-term, Strides Arcolab stock has the potential to move up to Rs 205 where the key resistance is pegged. Medium-term investor can buy with the stop at Rs 118. Short-term traders can buy with a target of Rs 163 and stop at Rs 139. Yoganand D. Strides looks at four-fold increase in US revenues this year Strides to hive off R&D, sterile products entities Strides gets US nod for AIDS drug More Stories on : Pharmaceuticals | Stocks | Recommendation
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2009, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|